Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions

Pranab M. Barman, Lisa B. VanWagner – 20 November 2020 – In the changing landscape of liver transplantation (LT), we are now evaluating older and sicker patients with more cardiovascular comorbidities, and the spectrum of cardiovascular disease is uniquely physiologically impacted by end‐stage liver disease. Cardiac complications are now the leading cause of morbidity and mortality in LT recipients, and the pretransplant risk is exacerbated immediately during the transplant operation and continues long term under the umbrella of immunosuppression.

Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post–Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study

Jin Ge, Jennifer C. Lai, Justin Richard Boike, Margarita German, Nathaniel Jest, Giuseppe Morelli, Erin Spengler, Adnan Said, Alexander Lee, Alexander Hristov, Archita P. Desai, Shilpa Junna, Bhupesh Pokhrel, Thomas Couri, Sonali Paul, Catherine Frenette, Nathaniel Christian‐Miller, Marcela Laurito, Elizabeth C. Verna, Usman Rahim, Aparna Goel, Arighno Das, Stewart Pine, Dyanna Gregory, Lisa B.

Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections

Elisa Pose, Mar Coll, Celia Martínez‐Sánchez, Zhutian Zeng, Bas G. J. Surewaard, Cristina Català, María Velasco‐de Andrés, Juan José Lozano, Sílvia Ariño, David Fuster, Aida Niñerola‐Bazán, Isabel Graupera, Érica Muñoz, Francisco Lozano, Pau Sancho‐Bru, Paul Kubes, Pere Ginès – 20 November 2020

Subscribe to